Business Description
OKYO Pharma Ltd
ISIN : GG00BMFG5F62
Share Class Description:
STU:OK10: ADRTotal Employee Number:
4Description
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 110.72 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.4 | |||||
3-Year EPS without NRI Growth Rate | 26.7 | |||||
3-Year FCF Growth Rate | 22.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 54.09 | |||||
14-Day RSI | 54.88 | |||||
6-1 Month Momentum % | -13.6 | |||||
12-1 Month Momentum % | 107.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 2.43 | |||||
Cash Ratio | 2.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -28.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -796.74 | |||||
ROA % | -91.65 | |||||
ROIC % | -3916.59 | |||||
3-Year ROIIC % | -239.5 | |||||
ROC (Joel Greenblatt) % | -282266.67 | |||||
ROCE % | -753.83 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.15 | |||||
Price-to-Tangible-Book | 6.97 | |||||
EV-to-EBIT | -9.95 | |||||
EV-to-Forward-EBIT | -1.56 | |||||
EV-to-EBITDA | -9.95 | |||||
EV-to-FCF | -14.17 | |||||
| Price-to-Net-Current-Asset-Value | 7.2 | |||||
| Price-to-Net-Cash | 7.2 | |||||
Earnings Yield (Greenblatt) % | -10.05 | |||||
FCF Yield % | -6.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OKYO Pharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.06 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 33.6 | ||
| 14-Day RSI | 54.88 | ||
| 14-Day ATR (€) | 0.00002 | ||
| 20-Day SMA (€) | 2.16 | ||
| 12-1 Month Momentum % | 107.69 | ||
| 52-Week Range (€) | 0.855 - 2.7 | ||
| Shares Outstanding (Mil) | 40.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OKYO Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OKYO Pharma Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 09:30 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 2.16 (+0.00%) | ||
| Guidance call for 2026 | 2026-07-28 | 2.16 (+0.00%) | ||
| Annual report for 2026 | 2026-07-20 | 2.16 (+0.00%) | ||
| General meeting for 2025 | 2025-12-16 09:30 | 2.16 (+0.00%) | ||
| Annual report for 2025 | 2025-08-12 | 2.64 (+4.76%) | ||
| Second quarter earnings results for 2025 | 2025-01-29 | 0.94 (+4.47%) | ||
| General meeting for 2024 | 2024-12-12 09:30 | 0.97 (+4.32%) | ||
| H.C. Wainwright 4th Annual Ophthalmology Virtual Conference | 2024-08-15 07:00 | 0.84 (+0.00%) | ||
| Annual report for 2024 | 2024-08-13 | 0.83 (+0.00%) |
Show
Entries
OKYO Pharma Ltd Frequently Asked Questions
What is OKYO Pharma Ltd(STU:OK10)'s stock price today?
The current price of STU:OK10 is €2.16. The 52 week high of STU:OK10 is €2.70 and 52 week low is €0.86.
When is next earnings date of OKYO Pharma Ltd(STU:OK10)?
The next earnings date of OKYO Pharma Ltd(STU:OK10) is 2027-01-30 Est..
Does OKYO Pharma Ltd(STU:OK10) pay dividends? If so, how much?
OKYO Pharma Ltd(STU:OK10) does not pay dividend.
Press Release
Articles on OKYO Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers